Antibody-drug conjugates
Oncology· 9 reviewed drugs· 16629 cited findings behind them
What the regulatory reviews cover
The following Antibody-drug conjugates have undergone regulatory review and are included in this library: Enhertu, Trodelvy, Padcev, Adcetris, Kadcyla, Elahere, Tivdak, Zynlonta, and Datroway. These drugs have been reviewed for various indications, including HER2-positive solid tumors, triple-negative breast cancer, urothelial cancer, large B-cell lymphoma, HER2-positive breast cancer, ovarian cancer, cervical cancer, and diffuse large B-cell lymphoma.
Different drugs were studied in different trials, and therefore the reported figures are not directly comparable head-to-head. For instance, Enhertu demonstrated an Objective response rate (ORR) of 60.3%. Trodelvy showed a Median overall survival time of 13.0. Padcev reported an Objective Response Rate (ORR) of 32.2%. Kadcyla had a Median Progression-free survival of 14.2. Tivdak's median OS (months) was 11.7. Zynlonta's Objective response rate (ORR) was 21.2%. Datroway's Median OS (months) was 23.9.
The drugs — one cited result each
| Enhertu Daiichi Sankyo Company, Limited | Objective response rate (ORR): 60.3 Daiichi Sankyo Company, Limited — Enhertu FDA Review (BLA761, p.18 |
| Trodelvy Gilead Sciences, Inc. | Median overall survival time: 13.0 Gilead Sciences, Inc. — Trodelvy FDA Review (BLA761115, ORIG, p.65 |
| Padcev Astellas Pharma Inc. | Objective Response Rate (ORR): 32.2 Astellas Pharma Inc. — Padcev FDA Review (BLA761137, ORIG 1,, p.24 |
| Adcetris Takeda Pharmaceutical Company Limited | Overall objective response rate (ORR): 75 Adcetris EMA EPAR pu, p.55 |
| Kadcyla Roche Holding AG | Median Progression-free survival: 14.2 Roche Holding AG — Kadcyla EMA EPAR public assessment report, p.74 |
| Elahere AbbVie Inc. | median Overall Survival (OS): 13.2 AbbVie Inc. — Elahere EMA EPAR public assessment report (EME, p.16 |
| Tivdak Genmab A S | median OS (months): 11.7 Genmab A S — Tivdak EMA EPAR public assessment report (EMEA/, p.128 |
| Zynlonta Swedish Orphan Biovitrum | Objective response rate (ORR): 21.2% Swedish Orphan Biovitrum — Zynlonta EMA EPAR public assessme, p.13 |
| Datroway Daiichi Sankyo Company, Limited | Median OS (months): 23.9 Daiichi Sankyo Company, Limited — Datroway EMA EPAR public a, p.11 |
Different drugs were studied in different trials — these figures are not head-to-head comparisons.
Explore the full evidence
Every finding behind these drugs — searchable, comparable and answerable in plain language — is in the Oncology research library →
Lists reflect the regulatory review documents in this library, not all therapies that exist. Educational reference only — not medical or investment advice.